NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
NuVasive (NUVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Hold on to Globus Medical Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Globus Medical (GMED) on its stellar segmental performance.
Buy These 5 Stocks With Upgraded Broker Ratings for 2020
by Swayta Shah
When a broker upgrades a stock, you can rely on their judgment. Nonetheless, you should also take into account few other factors to ensure steady returns.
Here's Why You Should Retain Integra LifeSciences Stock Now
by Zacks Equity Research
Investors can hold on to Integra LifeSciences (IART) stock in their portfolio owing to solid prospects.
Insulet Rides on Innovation, Omnipod's Wider Market Appeal
by Zacks Equity Research
The full-market commercial launch of Insulet's (PODD) Omnipod DISPLAY and Omnipod VIEW apps for use with the Omnipod DASH System is encouraging.
Medtronic (MDT) Inks Deal to Focus on Value-Based Healthcare
by Zacks Equity Research
With shared financial responsibility between ChristianaCare and Medtronic (MDT), this coordinated effort will improve patient outcomes at reduced cost.
ResMed (RMD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
ResMed (RMD) gains from impressive performance of its SaaS business.
Cardiovascular Systems Sees Peripheral OAS Micro Crown Success
by Zacks Equity Research
This is a major achievement for Cardiovascular Systems (CSII) toward strengthening its portfolio for the treatment of CLI.
Tandem Diabetes Gets FDA Nod for t:slim X2 Insulin Pump
by Zacks Equity Research
The FDA nod for Tandem Diabetes' (TNDM) t:slim X2 insulin pump with Control-IQ will speed up its pump shipments within the United States and grow its clientele.
Neogen's Food Safety Business Thrives on Ergot Alkaloids Test
by Zacks Equity Research
The newly-developed Reveal Q+ MAX test is likely to fortify Neogen's (NEOG) presence in the global food allergen testing market.
Intersect ENT (XENT) Grows on Innovation Despite Cost Woes
by Zacks Equity Research
The latest offering in Intersect ENT's (XENT) SINUVA portfolio is specific J code - J7401.
Walgreens Extends Deal to Form GPO With Retail Giant Kroger
by Zacks Equity Research
Per Walgreens (WBA), its alliance with Kroger will lead to supply chain efficiencies, capitalizing on their joint resources.
Here's Why You Should Hold on to Quest Diagnostics Stock Now
by Zacks Equity Research
Investors can retain Quest Diagnostics (DGX) stock in their portfolio, thanks to solid prospects.
Here's Why You Should Add Omnicell to Your Portfolio Now
by Zacks Equity Research
Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.
Omnicell (OMCL) Partners With Kit Check to Offer Bluesight
by Zacks Equity Research
This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.
NUVA vs. HAE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUVA vs. HAE: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth
by Zacks Equity Research
Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.
Amedisys (AMED) Benefits From Home Health and Personal Care
by Zacks Equity Research
Amedisys' (AMED) impressive performance in the newly-unveiled Personal Care segment is appreciative.
Thermo Fisher (TMO) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.
NuVasive Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
NuVasive (NUVA) is optimistic about maintaining the momentum on several positive developments.
NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Myriad Genetics Reports Favorable Study Result on Prequel
by Zacks Equity Research
Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.
Boston Scientific's Watchman Implant Study Results Encourage
by Zacks Equity Research
These study results are expected to be a major breakthrough for Boston Scientific's (BSX) Cardiovascular segment.
NuVasive Advances on Global Footprint Despite Pricing Woes
by Zacks Equity Research
Within NuVasive's (NUVA) U.S. Spinal Hardware business, a strong uptick in case volume and tangible growth in the XLIF and ALIF franchises are major upsides.
Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits
by Zacks Equity Research
Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.